Related Experiment Video

Updated: May 16, 2025

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.0K

PLA2G7 promotes immune evasion of bladder cancer through the JAK-STAT-PDL1 axis

Ding Peng1, Wuping Yang1, Tianyu Tang1

  • 1Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang Province, 310003, PR China.

Cell Death & Disease
|April 1, 2025
PubMed

Insights

Phospholipase A2 Group VII (PLA2G7) is elevated in bladder cancer, promoting tumor growth and PD-L1 expression. Targeting PLA2G7 offers a novel immunotherapy strategy by enhancing T-cell infiltration and synergizing with other therapies.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Immune checkpoint inhibitors targeting Programmed cell death 1 (PD-1) and Programmed death ligand-1 (PD-L1) show clinical benefits in bladder cancer.
  • Low response rates to current immunotherapies necessitate alternative treatment strategies.

Purpose of the Study:

  • To investigate the role of Phospholipase A2 Group VII (PLA2G7) in bladder cancer.
  • To explore PLA2G7 as a potential therapeutic target for bladder cancer immunotherapy.

Main Methods:

  • Investigated PLA2G7 expression and its correlation with prognosis in bladder cancer.
  • Utilized in vitro knockdown experiments to assess PLA2G7's effect on cancer cell behavior and PD-L1 expression.
  • Analyzed the JAK-STAT pathway involvement in PLA2G7-mediated PD-L1 regulation.
  • Evaluated the synergistic effect of PLA2G7 suppression with anti-CTLA4 therapy in syngeneic mouse models.
  • Identified ETS1 as a regulator of PLA2G7 overexpression.

Main Results:

  • PLA2G7 is significantly elevated in bladder cancer, correlating with worse prognosis.
  • PLA2G7 knockdown inhibits PD-L1 expression and suppresses tumor growth by increasing CD8+ T-cell infiltration.
  • PLA2G7 promotes PD-L1 expression via the JAK-STAT pathway, upregulating STAT1 and STAT3 phosphorylation.
  • PLA2G7 suppression combined with anti-CTLA4 therapy demonstrates synergistic effects on tumor burden and survival.
  • ETS1 was identified as a promoter of PLA2G7 overexpression in bladder cancer cells.

Conclusions:

  • PLA2G7 is a key regulator of PD-L1 expression and tumor immunity in bladder cancer.
  • Targeting the ETS1-PLA2G7-STAT pathway presents a novel immunotherapeutic strategy for bladder cancer.
  • PLA2G7 inhibition may enhance the efficacy of existing immunotherapies.

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

357
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.1K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.2K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K